In the 2025 China Pharmaceutical Innovation Index, Sino Biopharmaceutical demonstrated a distinctive and robust innovation profile, ranking third in innovation, slightly ahead of its fourth-place position in invention. As one of China's earliest pharmaceutical conglomerates to establish a fully integrated innovation ecosystem, this ranking underscores the company's defining characteristics: exceptional efficiency in translating R&D outcomes into market value, coupled with substantial depth and competitiveness in its future pipeline. This reflects a balanced development model characterized by sustained accumulation and comprehensive capabilities.

The cornerstone of this achievement lies in Sino Biopharmaceutical‘s successfully established broad and deep product portfolio and a powerful commercialization platform. Leveraging core subsidiaries like Chia Tai Tianqing (CTTQ), the company has amassed extensive market access and marketing expertise in hepatology, oncology, respiratory diseases, and anti-infectives. The rapid volume growth following the inclusion of multiple innovative drugs in the NRDL in 2024 provided strong momentum. Driven by a rich innovative product matrix, revenue from novel drugs surged 21.9% year-on-year to RMB 12.08 billion (USD $1.70 billion) in 2024, accounting for 41.8% of total revenue. Oncology drug sales reached RMB (10.69 billion (USD $1.51 billion), representing 37.2% of total revenue and serving as a key growth anchor.

Sino Biopharmaceutical exemplifies a steady transition from "generic-innovative hybrid" to "first-in-class innovation," emerging as the company with the highest number of approved Class 1 innovative drugs in 2024. In oncology, building on the success of anlotinib , a multi-target tyrosine kinase inhibitor (TKI), the company continues to expand its indications. Combination therapies featuring anlotinib and the PD-L1 inhibitor Benmelstobart have demonstrated promising efficacy data in various cancers, including endometrial carcinoma, small cell lung cancer, and renal cell carcinoma, solidifying the company's leading position in oncology. Its ROS1 inhibitor unecritinib (Amboniy) is the first domestically developed targeted therapy approved for ROS1-positive locally advanced or metastatic NSCLC in adults. The TQ-B3101-II-01 Phase II study reported an ORR of 81.08% and a Duration of Response (DOR) of 20.3 months. Sino Biopharmceutiucal has also strategically deepened its focus on breast cancer, with candidates like the CDK inhibitor Culmerciclib poised to become the next major growth driver in oncology following its lung cancer portfolio.

Concurrently, the company achieved significant breakthroughs in respiratory diseases. TQC2731 is currently in Phase III trials in China for severe asthma, positioning it as the most advanced domestically developed TSLP monoclonal antibody. TQC3721, a PDE3/4 inhibitor targeting conditions like COPD, ranks second globally in development progress. Several other promising innovative respiratory drugs are in the pipeline, marking the company's successful entry into the import-dominated respiratory therapeutics market and opening a new growth avenue.

In hepatology, Sino Biopharmaceutical has made significant progress through active external collaboration and in-licensing. Lanilamod, a pan-PPAR agonist for which Sino holds Greater China development rights, is the first MASH drug candidate in China to enter Phase III clinical trials. The company plans to submit an NDA in China in 2026, potentially addressing a significant unmet medical need. In collaboration with Anyuan Pharmaceutical, TQA2225 for MASH treatment has completed patient enrollment for its Phase II trial, making it the most advanced drug candidate of its class in China and a potential first-in-class FGF21 fusion protein therapy upon approval. Clinical data suggest FGF21's potential to reverse liver fibrosis in F3/F4 MASH patients, positioning it to fill a critical gap in treating advanced MASH.

Throughout 2024, Sino Biopharmaceutical also deepened strategic collaborations with various partners, including Liaxin, Youzhiyou, Xianweda, and Qingpu Biopharmaceutical, for the co-development of innovative assets. Regarding global expansion, Sino has adopted a pragmatic, stepwise strategy. This involves in-licensing innovative therapies from international players like Boehringer Ingelheim while simultaneously advancing its proprietary innovative drugs for overseas registration, targeting global unmet clinical needs.

Sino Biopharmaceutical's position in both innovation rankings accurately reflect its unique positioning and core competitiveness within China's pharmaceutical innovation landscape. Its innovation capability slightly outpacing its invention capability precisely indicates a results-oriented company adept at efficiently transforming both internal R&D investments and externally sourced assets into commercial success. It embodies the strength of a "Robust Platform Company," navigating the competitive landscape of innovative drugs with steady and determined progress.